Multiple myeloma Survivorship Follow-Up Questions

Multiple myeloma belongs to a family NCI's PDQ summary calls plasma cell neoplasms. Three others sit in that family. MGUS, short for monoclonal gammopathy of undetermined significance. Isolated plasmacytoma of bone. And extramedullary plasmacytoma. All are marked by an M protein, short for myeloma protein.

The American Cancer Society's 2026 projection for the US is 36,000 new cases of multiple myeloma and 10,850 deaths.

The shape of follow-up differs from most cancers. After an autologous stem cell transplant, PDQ says patients are offered lenalidomide maintenance therapy. So the survivorship visit is often a treatment visit.

PDQ's reasoning for lenalidomide maintenance is specific. It cites steady gains in PFS, meaning time before the myeloma grows again. It cites occasional gains in overall survival. Then it names the counterweight. Short-term toxicity, long-term toxicity, and cost may stop it being used at all.

For high-risk disease, especially with the chromosome changes del(17p) or t(14;16), PDQ says bortezomib maintenance may be required, with or without lenalidomide. It then says plainly that this approach is not evidence-based and needs confirmatory trials.

That is unusual candor, and it is useful. It means a question about why a particular maintenance drug was chosen has a real answer, not a protocol number.

Long maintenance raises a fair worry about second cancers, and PDQ carries numbers rather than reassurance.

One meta-analysis pooled 3,254 patients from seven randomized trials. Second blood cancers turned up in 3.1% of people given lenalidomide. The figure was 1.4% in those not given it. The hazard ratio was 3.8, with a 95% confidence interval of 1.15 to 12.62 and a P value of .029.

The detail that matters most is where that risk sat. PDQ says it was confined to one pairing: lenalidomide with melphalan, an older chemo drug. The hazard ratio there was 4.86. Risk was not higher when lenalidomide was paired with cyclophosphamide or dexamethasone.

A separate look back covered almost 4,000 people with relapsed or refractory disease across 11 trials. It suggested more nonmelanoma skin cancers. Skin checks follow from that finding, not from a general rule.

Measurable residual disease, or MRD, means cancer cells still detectable in the bone marrow at very low levels. PDQ calls MRD assessment mandatory for judging efficacy in clinical trials.

Then it asks its own question: does MRD testing outside a trial actually improve outcomes by guiding treatment choice or duration?

Its answer has two parts. Reaching MRD negativity after induction is linked to better PFS and better survival. But no data show that this marker improves outcomes by changing what comes next. And no data show that lasting MRD negativity allows cutting back or stopping maintenance.

PDQ does note that MRD testing from a blood sample looks feasible, using next-generation flow and mass spectroscopy, which is less invasive than a bone marrow test.

So a negative MRD result is good news about biology. Per this summary, it is not yet a reason to stop.

Myeloma bone disease comes from overactive osteoclasts. Those are the cells that break down bone. PDQ says two bisphosphonates are used most often, pamidronate and zoledronate, both given by vein. Denosumab works too. It is an antibody against RANKL, given under the skin. PDQ highlights it when kidney problems rule out bisphosphonates.

The zoledronate evidence is strong. A randomized trial of 1,970 newly diagnosed patients compared it against oral clodronate. At a median 3.7 years, median overall survival rose from 44.5 months to 50.0 months, with a hazard ratio of 0.84 and a P value of .0118. Skeletal-related events fell to 27% from 35%. PDQ grades this Level of evidence A1.

A Cochrane network meta-analysis confirmed that survival result. It added a practical figure. Between 6 and 15 patients need bisphosphonate treatment to prevent one skeletal event.

On duration, PDQ says bisphosphonates usually run monthly by vein for 2 years. After that they either continue at the same pace or drop to every 3 to 4 months, if bone disease is still active. One trial compared monthly zoledronate with every-12-week dosing. It enrolled 1,822 patients, but only 278 had myeloma. PDQ says that subgroup was underpowered to prove the longer gap was as good.

The cost is uncommon but serious. PDQ puts long-term complications at 3% to 5%, and names osteonecrosis of the jaw and avascular necrosis of the hip.

PDQ ties lenalidomide dose cuts to creatinine clearance, a gauge of how well the kidneys filter. As that number falls, the daily amount is reduced, or the same capsule is spaced out to every other day; for people on dialysis the capsule is timed to the day after a session. Your haematologist sets all of this from your own blood results, and it is worth asking at review whether your current dose still matches your latest clearance.

PDQ also notes that lenalidomide raises the risk of deep vein thrombosis and pulmonary embolism. For people without extra clotting risk factors, a single low-dose aspirin a day — the 81 mg tablet — is enough, though only start or stop it on your own team's say-so, since it is not right for everyone. With multiple risk factors, PDQ says stronger anticoagulants should be considered.

PDQ says patients on a bortezomib regimen need prophylaxis against herpes zoster. That is the virus behind shingles. The usual drugs are valacyclovir or acyclovir. PDQ frames this as a standing instruction, not an extra.

It also explains why bortezomib is given under the skin rather than by vein: the nerve damage seen with intravenous dosing was much more severe. PDQ adds that bortezomib is preferred when kidney function is impaired.

This summary sets no follow-up interval. It gives no schedule for repeating M protein, free light chain, calcium, or creatinine tests. It gives no vaccination schedule for myeloma. It does not describe kyphoplasty or vertebroplasty for spine fractures.

Those gaps are worth naming out loud rather than filling in with guesswork, because a team following a different guideline will have real numbers to quote.

• Which maintenance drug am I on, and is that choice evidence-based for my risk group?
• Did my earlier treatment include melphalan, given where PDQ places the second-cancer signal?
• Am I due for a skin check, given the nonmelanoma skin cancer finding with lenalidomide?
• How long will the bone drug continue, and is the schedule monthly or every 3 to 4 months?
• Do I have zoster prophylaxis in place while on bortezomib?

The disease itself is described in multiple myeloma. What happens when it comes back is covered in relapsed multiple myeloma. Broader life-after-treatment ground is in survivorship.

• NCI PDQ: plasma cell neoplasms, HP version